← Back to Screener
IN8bio, Inc. Common Stock (INAB)
Price$1.50
Favorite Metrics
Price vs S&P 500 (26W)-37.77%
Price vs S&P 500 (4W)-17.78%
Market Capitalization$14.77M
All Metrics
Book Value / Share (Quarterly)$2.82
P/TBV (Annual)1.03x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.30
Price vs S&P 500 (YTD)-39.83%
EPS (TTM)$-4.78
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-4.78
EPS (Annual)$-4.44
ROI (Annual)-69.79%
Cash / Share (Quarterly)$2.77
ROA (Last FY)-60.22%
EBITD / Share (TTM)$-3.90
ROE (5Y Avg)-112.99%
Cash Flow / Share (Annual)$-1.30
P/B Ratio0.54x
P/B Ratio (Quarterly)0.39x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-207.00x
ROA (TTM)-88.07%
EPS Incl Extra (Annual)$-4.44
Current Ratio (Annual)8.82x
Quick Ratio (Quarterly)8.65x
3-Month Avg Trading Volume0.21M
52-Week Price Return-68.94%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.56
52-Week High$5.82
EPS Excl Extra (Annual)$-4.44
CapEx CAGR (5Y)-10.74%
26-Week Price Return-30.88%
Quick Ratio (Annual)8.65x
13-Week Price Return-35.34%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)8.82x
Enterprise Value$-12.026
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.77
3-Month Return Std Dev86.08%
Net Income / Employee (TTM)$-1
ROE (Last FY)-70.54%
EPS Basic Excl Extra (Annual)$-4.44
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-4.78
ROI (TTM)-108.21%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.93
Price vs S&P 500 (52W)-103.58%
Year-to-Date Return-35.90%
5-Day Price Return8.70%
EPS Normalized (Annual)$-4.44
ROA (5Y Avg)-83.12%
Month-to-Date Return1.35%
Cash Flow / Share (TTM)$-1.05
EBITD / Share (Annual)$-4.14
LT Debt / Equity (Annual)3.57x
ROI (5Y Avg)-107.35%
LT Debt / Equity (Quarterly)0.14x
EPS Basic Excl Extra (TTM)$-4.78
P/TBV (Quarterly)1.32x
P/B Ratio (Annual)0.39x
Book Value / Share (Annual)$2.82
Price vs S&P 500 (13W)-37.73%
Beta0.13x
Revenue / Share (TTM)$0.00
ROE (TTM)-111.30%
52-Week Low$1.17
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.10
4.10
4.10
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
INABIN8bio, Inc. Common Stock | — | — | — | — | $1.50 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
IN8bio Inc is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid and liquid tumors using allogeneic, autologous, and engineered cell approaches. Lead programs include INB-400 for glioblastoma and INB-100 for high-risk leukemias, with additional candidates in earlier development stages.